A Phase II Trial of Osimertinib With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Bevacizumab (Primary) ; Osimertinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Jul 2017 Planned End Date changed from 1 Jan 2020 to 1 Jul 2020.
- 03 Jul 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Jul 2020.
- 23 Apr 2017 Planned initiation date changed from 1 Dec 2017 to 29 Dec 2017.